Although biliary tract cancer (BTC) is a rare type of cancer throughout the world, it is more prevalent in East Asia and Latin America than in other countries ([@bib10]; [@bib17]). According to 'Demographic Statistics in Japan (2009)\' (compiled by the Statistics and Information Department, Minister\'s Secretariat, Ministry of Health, Labour, and Welfare (MHLW)), the number of deaths due to BTC was 17 311 in 2007, making this cancer the sixth leading cause of cancer death in Japan.

Despite great progress in diagnostic imaging, most cases of BTC are diagnosed as advanced and inoperable. Even if the tumour is not locally advanced, the primary tumour site is often contiguous with vital organs such as the liver, pancreas, or duodenum, or with major vessels such as the portal vein or hepatic artery. This anatomical peculiarity precludes resection of tumours in many cases. Furthermore, even if curative-intent surgical resection is performed, the cancer often relapses due to its invasive nature and its anatomical characteristics.

Systemic chemotherapy is usually indicated for patients with unresectable, advanced BTC or for those who have relapsed after operation; however, no standard treatment has yet been established for such patients. Gemcitabine hydrochloride is a deoxycytidine derivative that inhibits DNA elongation through intracellular phosphorylation of ribonucleotide reductase. In Japan, a single-arm Phase II study in patients with unresectable BTC confirmed that gemcitabine monotherapy had moderate efficacy and manageable toxicity, both of which were comparable with approved treatments for other cancers ([@bib12]).

As gemcitabine had also been found to exhibit synergistic effects on cytotoxic activity *in vitro* and *in vivo* when combined with cisplatin ([@bib16]; [@bib2]), clinical studies were conducted in various cancers with this combination. Results from these studies eventually led to use of the gemcitabine plus cisplatin (GC) combination as one of the standard treatments for non-small cell lung cancer and bladder cancer.

The combination of GC has also been studied by many researchers for the treatment of BTC ([@bib13]; [@bib5]; [@bib15]; [@bib9]). So far, the largest randomised Phase III study has been the recent UK ABC-02 study, in which the efficacy and safety of gemcitabine 1000 mg m^−2^ alone *vs* the combination of gemcitabine 1000 mg m^−2^ plus cisplatin 25 mg m^−2^ was evaluated by British research groups (Cancer Research UK and University College London). That study was initiated as a randomised phase II study with gemcitabine alone *vs* GC (UK ABC-01 study) and then was expanded to a phase III study (ABC-02 study) ([@bib20], [@bib21]).

Our study was planned to follow-up on an earlier study of gemcitabine monotherapy conducted in Japanese BTC patients ([@bib12]). Given the encouraging results from the UK ABC-01 study, we conducted this study to (1) evaluate both gemcitabine monotherapy and the GC combination in Japanese BTC patients, and (2) determine whether benefits similar to those observed in the UK study could be obtained for the combination regimen.

The primary objective of the study was to compare the 1-year survival rate in patients with BTC who received one of these two therapies. The secondary objectives included response rate, progression-free survival (PFS) and assessment of safety.

Materials and methods
=====================

Study design
------------

This was a multicentre, randomised phase II study to evaluate the efficacy and safety of GC combination compared with single-agent gemcitabine in chemotherapy-naive patients with locally advanced or metastatic BTC. Patients were randomised to either single-agent gemcitabine 1000 mg m^−2^ on days 1, 8 and 15 of a 28-day cycle (G-arm) or cisplatin 25 mg m^−2^ followed by gemcitabine 1000 mg m^−2^ on days 1, 8 of a 21-day cycle (GC-arm). Randomisation was stratified by primary site (gallbladder cancer or other BTC) and the presence or absence of primary tumour.

Eligibility criteria
--------------------

Eligible patients met the following criteria: histologically confirmed unresectable locally advanced or metastatic cancer of the biliary tract; no history of earlier chemotherapy; performance status of 0 or 1; a life expectancy of at least 3 months; at least 20 years of age at the time of study entry; adequate function of major organs (haemoglobin ⩾10 g per 100 ml, white blood cells ⩾3000/mm^3^, neutrophils ⩾1500/mm^3^, platelets ⩾100 000/mm3, AST/ALT/ALP ⩽3 times upper limit of normal (ULN), total bilirubin ⩽2 times ULN, ⩽3 times ULN for patients with obstructive jaundice or metastases to the liver, serum creatinine ⩽1.5 times ULN, creatinine clearance or 24-h creatinine clearance ⩾45 ml min^−1^).

This study followed the ethical principles that have their origins in the Declaration of Helsinki, and was conducted in accordance with the protocol, the 'ordinance on Good Clinical Practice\' and related regulations. Written informed consent was obtained from all patients who were considered eligible for participation in this study before enrolment. The Efficacy and Safety Evaluation Committee, an independent review board, was consulted if any efficacy and safety issues arose in the study.

Study treatment
---------------

The assigned treatment was given for a minimum of 12 weeks (at least four cycles in the GC-arm and three cycles in the G-arm) and continued to a maximum of 48 weeks (up to 16 cycles in the GC-arm and up to 12 cycles in the G-arm), unless disease progression (PD) was evident, an intolerable adverse event occurred or the patient was required to withdraw from the study.

Efficacy and safety assessment
------------------------------

All patients who received at least 1 dose of the study drug were included in the efficacy and safety assessment. Response rate was evaluated according to the Response Evaluation Criteria in Solid Tumors. Evaluation of tumours after patient randomisation was performed every 6 weeks until PD. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0).

Statistical design and analysis
-------------------------------

The sample size was calculated by the selection method of Simon ([@bib18]), which is based on the proposition that GC combination therapy is selected if the 1-year survival rate for the GC-arm is higher than that for the gemcitabine arm. We assumed a 1-year survival rate of 25% for the G-arm and 35% for GC-arm ([@bib12]; [@bib13]). With these assumptions, 30 patients per arm were needed to appropriately select the combination therapy with a probability of ⩾80%. To optimise safety and efficacy information, the sample size was set to 42 patients per arm.

The Kaplan--Meier method was used to estimate 1-year survival (primary outcome), PFS and 6-month PFS rates (secondary outcomes) for each treatment arm; 95% confidence intervals (CIs) were calculated. A Cox proportional hazards model was used to calculate the hazard ratio, 95% CI and its two-tailed *P*-value. Fisher\'s exact test was used to compare the patient characteristics, response and disease control rates, and toxicities between the two treatment arms. The exact CIs were calculated based on binomial distributions.

Results
=======

Patients
--------

This study was carried out from September 2006 to October 2008 at nine study centres in Japan. Eighty-four patients were randomised to either gemcitabine monotherapy (G-arm) or GC combination (GC-arm). One patient assigned to the GC-arm was not treated because the general condition of the patient deteriorated before study treatment. All of the remaining 83 patients, 41 in the GC-arm and 42 in the G-arm, received at least 1 dose of study treatment. Efficacy and safety were evaluated for each of these 83 patients ([Figure 1](#fig1){ref-type="fig"}). Demographic variables ([Table 1](#tbl1){ref-type="table"}) were well balanced between the two treatment arms, except for patients with ampullary carcinoma (4 in GC-arm, 0 in G-arm).

Drug exposure and duration of the treatments
--------------------------------------------

A total of 247 (median 6.0) and 203 (median 4.0) cycles were administered in the GC-arm and G-arm, respectively. Relative dose intensities were 78.9% for gemcitabine and 79.0% for cisplatin in the GC-arm, and 87.4% for gemcitabine in the G-arm. Three patients in the GC-arm and two patients in the G-arm completed 48 weeks treatment.

Efficacy
--------

A total of 83 patients were evaluable for tumour response according to the protocol, 41 in the GC-arm and 42 in the G-arm. No complete tumour responses were observed. In total, eight patients in the GC-arm had a partial response (PR) compared with five patients in the G-arm (PR 19.5 *vs* 11.9%). In addition, 20 patients had stable disease in the GC-arm *vs* 16 patients in the G-arm (SD 48.8 *vs* 38.1%). The disease control rate (CR+PR+SD) was 68.3% (95% CI: 51.9, 81.9) *vs* 50.0% (95% CI: 34.2, 65.8) in favour of the combination therapy. The 1-year survival rate (39.0 *vs* 31.0%), median survival time (11.2 months *vs* 7.7 months) and median PFS (5.8 months *vs* 3.7 months) were better for the GC-arm *vs* G-arm ([Figure 2](#fig2){ref-type="fig"}). The hazard ratio between the GC and G-arms was 0.69 (95% CI: 0.42, 1.13) for overall survival (OS) and 0.66 (95% CI: 0.41, 1.05) for PFS ([Table 2](#tbl2){ref-type="table"}).

As shown in [Table 3](#tbl3){ref-type="table"}, the prognosis for patients with gallbladder cancer was worse than that for patients with non-gallbladder cancer; however, the median survival times were longer with the GC combination in gallbladder cancer patients (9.1 months *vs* 6.7 months), as well as in patients with non-gallbladder cancer (13.0 months *vs* 8.0 months). The prognosis for patients with primary tumours was worse than that for patients without primary tumours; however, the GC therapy showed longer median survival time in both patient subgroups (9.4 months *vs* 7.4 months in the patients with primary tumours, 16.1 months *vs* 12.7 months in the patients without primary tumours).

Safety
------

All adverse events observed in this study were predictable and manageable based on the safety profile of GC. As shown in [Table 4](#tbl4){ref-type="table"}, the most common grade 3 or higher adverse events (⩾25%) were neutropenia (56.1%), thrombocytopenia (39.0%), haemoglobin decrease (36.6%), RBC decrease (34.1%), leukopenia (29.3%) and *γ*-GTP increase (29.3%) in the GC-arm, and neutropenia (38.1%) and *γ*-GTP increase (35.7%) in the G-arm. The incidence of haematotoxicity was higher in the GC-arm; grade 3 or more serious C-reactive protein increase was detected only in the monotherapy arm.

There were no treatment related deaths. Most of the patients recovered from the above adverse events by reducing or discontinuing the study treatment.

Post-study chemotherapy
-----------------------

Thirty patients in the GC-arm received post-study chemotherapy including S-1, tegaful/gimeracil/oteracil potassium (19 patients), gemcitabine (10 patients) and tegaful/uracil (1 patient). In the G-arm, 33 patients received post-study chemotherapy including S-1 (20 patients), gemcitabine (11 patients), cisplatin/fluorouracil (1 patient) and doxorubicin/tegaful/uracil (1 patient).

Discussion
==========

Although this study (BT22 study) showed that gemcitabine monotherapy and the GC combination were both active in Japanese patients with advanced BTC, a superior benefit was obtained with the combination treatment. In the GC/G-arms, the 1-year survival rate was 39.0%/31.0%, median survival time was 11.2/7.7 months and median PFS time was 5.8/3.7 months ([Table 2](#tbl2){ref-type="table"}).

The UK ABC-02 study, which was conducted with the same dose and regimen as this study ([@bib21]), showed a similar benefit for the GC combination. The respective median survival/PFS times in that study were 11.7/8.5 months in their GC-arm, and 8.2/6.5 months in their G-arm.

The hazard ratios reported in the ABC-02 study for OS (0.68, 95% CI: 0.53, 0.86) and PFS (0.70, 95% CI: 0.56, 0.88) compared well with the respective values from our study: 0.69 (95% CI: 0.42, 1.13) and 0.66 (95% CI: 0.41, 1.05). As the number of patients was based on Simon\'s selection method ([@bib18]), this study was not designed to compare and identify statistical significant differences between the two treatment arms. These hazard ratios strongly suggest that the GC combination has superior benefit compared with single-agent gemcitabine, even though there were no statistical significant differences in survival and PFS between the two arms in our study.

Although there have been many single-arm Phase II studies of the GC combination for BTC ([@bib19]; [@bib8]; [@bib3]; [@bib11]; [@bib20]), these results have never been distilled to one fixed dose and regimen of GC. Many previous studies of GC combination reported relatively higher response rates, but with more serious treatment-related adverse events ([@bib19]; [@bib8]; [@bib3]; [@bib11]). In the phase II study conducted by [@bib19], 17.85% of the patients who were treated with the GC combination required dose reduction, and in another Phase II study recently conducted by [@bib11], dose reductions and study withdrawals were required for 50% of the patients who received the combination therapy. In our study, we also observed more frequent adverse events with the doublet ([Table 4](#tbl4){ref-type="table"}). However, as shown in [Figure 1](#fig1){ref-type="fig"}, only seven patients (17%) discontinued from the study because of adverse events and four patients (9.7%) required dose adjustments in the GC-arm.

Overall, the toxicity observed in this study was manageable. Although interstitial pneumonia was detected in one patient from each of the arms, both patients recovered with appropriate treatment. One grade 3 renal failure and one grade 2 peripheral neuropathy were observed in GC-arm, in line with similar events seen in previous studies of the GC combination ([@bib19]; [@bib8]; [@bib3]; [@bib11]; [@bib20]). It is to be noted that despite the higher incidence of haematotoxicity in patients receiving the combination therapy, drug-caused myelosuppression did not result in febrile neutropenia or bleeding. Grade 3 or greater increases in C-reactive protein were observed only in the gemcitabine monotherapy-arm, also suggesting that the combination therapy did not increase neutropenic infections.

In this study, we stratified patients into those with gallbladder cancer and those with other BTCs. Gallbladder cancer has been reported to have a different biological behaviour ([@bib8]; [@bib4]; [@bib7]); furthermore, a pooled analysis by [@bib5]) revealed a higher response rate to chemotherapy and shorter OS for gallbladder cancer compared with other BTCs. As shown in [Table 3](#tbl3){ref-type="table"}, patients with gallbladder cancer showed worse survival than patients with other BTCs, this being consistent with previous reports ([@bib5]; [@bib22]). It is important to note that median survival times were longer with the GC combination in patients with gallbladder cancer (9.1 months *vs* 6.7 months), as well as in patients with non-gallbladder cancer (13.0 months *vs* 8.0 months), suggesting that the combination therapy has greater benefit than monotherapy in gallbladder cancer and other BTC patients.

Another stratification factor used for this study was the presence or absence of a primary tumour, not a commonly used stratification factor in clinical trials for advanced BTC. Locally advanced or metastatic cancer, the stratification factor used in the UK ABC-01 and UK ABC-02 studies, is more commonly used, as both of these have been shown to affect OS in advanced BTC ([@bib14]). However, considering the importance of surgical resection of the primary tumour, we decided to use this as a stratification factor for patients in this study. As shown in [Table 3](#tbl3){ref-type="table"}, patients with primary tumours showed remarkably worse survival than patients without primary tumours. However, because of the limited number of patients in our subanalyses, the results should be viewed with caution, and the usefulness of this prognostic factor should be evaluated in future studies. We will continue our efforts in collaboration with the UK ABC-02 study group to identify prognostic factors in a larger population, which may significantly affect clinical studies in BTC.

Despite the heterogeneous nature of BTC and the ethnic differences reported for this tumour type ([@bib6]; [@bib1]), the outcomes from this study showed striking similarity with the large-scale phase III study (UK ABC-02) results. This suggests that cisplatin 25 mg m^−2^ plus gemcitabine 1000 mg m^−2^ on days 1 and 8 of a 21-day cycle would be beneficial in the treatment of advanced BTC.
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###### Patient characteristics

                                                                                        **GC (*N*=41)**                      **GEM (*N*=42)**                      
  ------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------ -----------------------------------
  *Gender*                                                                                                                                                        
   Male                                                                                 18 (43.9)                            21 (50.0)                            0.662
   Female                                                                               23 (56.1)                            21 (50.0)                             
                                                                                                                                                                   
  *Age (year)*                                                                                                                                                    
   Median                                                                               65.0                                 66.5                                 0.0812[a](#t1-fn2){ref-type="fn"}
   Range                                                                                43--80                               49--78                                
                                                                                                                                                                   
  *PS*                                                                                                                                                            
   0                                                                                    34 (82.9)                            28 (66.7)                            0.129
   1                                                                                    7 (17.1)                             14 (33.3)                             
                                                                                                                                                                   
  *Primary tumour sites*                                                                                                                                          
   Extraheptic bile duct                                                                8 (19.5)                             11 (26.2)                            0.239
   Intraheptic bile duct                                                                14 (34.1)                            14 (33.3)                             
   Gallbladder                                                                          15 (36.6)                            17 (40.5)                             
   Ampulla                                                                              4 (9.8)                              0 (0.0)                               
                                                                                                                                                                   
  *Metastatic sites*                                                                                                                                              
   Liver                                                                                22 (53.7)                            20 (47.6)                            0.663
   Regional lymph nodes                                                                 23 (56.1)                            28 (66.7)                            0.372
   Distant lymph nodes                                                                  19 (46.3)                            18 (42.9)                            0.827
   Lung                                                                                 8 (19.5)                             7 (16.7)                             0.782
   Peritoneum                                                                           7 (17.1)                             7 (16.7)                             1.000
   Bone                                                                                 0 (0.0)                              1 (2.4)                              1.000
   Others                                                                               3 (7.3)                              3 (7.1)                              1.000
                                                                                                                                                                   
  *Initial onset or recurrence*                                                                                                                                   
   Initial onset                                                                        30 (73.2)                            32 (76.2)                            0.804
   Recurrence after surgery                                                             11 (26.8)                            10 (23.8)                             
                                                                                                                                                                   
  *Histological type*                                                                                                                                             
   Adenocarcinoma                                                                       39 (95.1)                            41 (97.6)                            0.616
   Adenosquamous cancer                                                                 2 (4.9)                              1 (2.4)                               
                                                                                                                                                                   
  *Disease stage (gallbladder cancer, extrahepatic bile duct cancer, ampulla cancer)*                                                                             
   IIA                                                                                  0 (0.0)                              0 (0.0)                              1.000
   IIB                                                                                  3 (7.3)[b](#t1-fn3){ref-type="fn"}   2 (4.8)[b](#t1-fn3){ref-type="fn"}    
   III                                                                                  2 (4.9)                              2 (4.8)                               
   IV                                                                                   16 (39.0)                            17 (40.5)                             
   Recurrence after surgery                                                             6 (14.6)                             7 (16.7)                              
                                                                                                                                                                   
  *Disease stage (intrahepatic bile duct cancer)*                                                                                                                 
   II                                                                                   0 (0.0)                              1 (2.4)[b](#t1-fn3){ref-type="fn"}   0.389
   IIIA                                                                                 0 (0.0)                              1 (2.4)                               
   IIIB                                                                                 0 (0.0)                              0 (0.0)                               
   IIIC                                                                                 0 (0.0)                              2 (4.8)                               
   IV                                                                                   9 (22.0)                             7 (16.7)                              
   Recurrence after surgery                                                             5 (12.2)                             3 (7.1)                               
                                                                                                                                                                   
  *Biliary drainage*                                                                                                                                              
   No                                                                                   25 (61.0)                            24 (57.1)                            0.824
   Yes                                                                                  16 (39.0)                            18 (42.9)                             
                                                                                                                                                                   
  *Previous therapy*                                                                                                                                              
   No                                                                                   30 (73.2)                            28 (66.7)                            0.855
   Surgery                                                                              11 (26.8)                            12 (28.6)                             
   Radiotherapy                                                                         0 (0.0)                              1 (2.4)                               
   Surgery and radiotherapy                                                             0 (0.0)                              1 (2.4)                               

Abbreviations: GC=gemcitabine and cisplatin; GEM=gemcitabine; PS=performance status.

*t*-test.

Patients were diagnosed as having unresectable disease with marked regional node metastases involving the proper hepatic artery and/or main portal vein.

###### Summary of time-to-event end points: overall response and survival

                                              **GC (*N*=41)**             **GEM (*N*=42)**          
  ------------------------------------------- --------------------------- ------------------------ -------
  *Overall response rate*                                                                          
   Complete response (CR)                     0 (0.0)                     0 (0.0)                   
   Partial response (PR)                      8 (19.5)                    5 (11.9)                  
   Stable disease (SD)                        20 (48.8)                   16 (38.1)                 
   Progressive disease (PD)                   9 (22.0)                    17 (40.5)                 
   Not evaluable (NE)                         4 (9.8)                     4 (9.5)                   
   Response rate (95% CI)                     19.5% (8.8, 34.9)           11.9% (4.0, 25.6)        0.380
   Disease control rate (CR+PR+SD) (95% CI)   68.3% (51.9, 81.9)          50.0% (34.2, 65.8)       0.119
                                                                                                    
  *Overall survival*                                                                               
   1-year survival rate (95% CI)              39.0% (23.7, 54.4)          31.0% (17.0, 44.9)        
   Median survival time (95% CI)              11.2 months (9.1, 12.5)     7.7 months (6.1, 11.0)    
   Hazard ratio (95% CI)                      0.69 (95% CI: 0.42, 1.13)   0.139                    
                                                                                                    
  *Progression-free survival (PFS)*                                                                
   Median PFS (95% CI)                        5.8 months (4.1, 8.2)       3.7 months (2.1, 5.3)     
   Hazard ratio (95% CI)                      0.66 (95%CI: 0.41, 1.05)    0.077                    
   6-Months PFS rate (95% CI)                 47.4% (31.4, 63.4)          27.7% (14.0, 41.5)        

Abbreviations: GC=gemcitabine and cisplatin; GEM=gemcitabine; CI=confidence interval.

###### Overall survival time by stratification factor

  **Median survival time (months)**                                                   
  ----------------------------------- ----------------------- ---------------------- -------
  *Tumour site*                                                                      
   Gallbladder                        9.1 (6.9, 11.6)         6.7 (4.2, 11.0)        0.675
   Non-gallbladder                    13.0 (9.2, ^\*\*\*^)    8.0 (6.1, 16.0)        0.110
                                                                                      
  *Primary tumour*                                                                   
   Presence of primary tumour         9.4 (8.7, 11.6)         7.4 (5.9, 8.5)         0.253
   Absence of primary tumour          16.1 (12.3, ^\*\*\*^)   12.7 (6.5, ^\*\*\*^)   0.389

Abbreviations: GC=gemcitabine and cisplatin; GEM=gemcitabine; CI=confidence interval.

^\*\*\*^denotes upper limits are not available.

###### Summary of maximum toxicity grades[a](#t4-fn2){ref-type="fn"} (incidence ⩾30%)

                                   **GC (*N*=41)**   **GEM (*N*=42)**                             
  ------------------------------- ----------------- ------------------ ------ ------ ----- ------ -------
  *Haematological*                                                                                
   WBC count decreased                  29.3                0           87.8   19.0    0    69.0  0.061
   Haemoglobin decreased                26.8               9.8          85.4   9.5    7.1   85.7  1.000
   Neutrophil count decreased           39.0               17.1         82.9   28.6   9.5   69.0  0.200
   Platelet count decreased             26.8               12.2         80.5   4.8    2.4   76.2  0.791
   RBC decreased                        34.1                0           75.6   14.3    0    78.6  0.798
   Haematocrit decreased                 4.9                0           58.5    0      0    54.8  0.826
                                                                                                   
  *Non-haematological*                                                                            
   Anorexia                               0                 0           80.5   4.8     0    61.9  0.090
   Nausea                                 0                 0           68.3    0      0    42.9  0.027
   Fatigue                                0                 0           58.5   2.4     0    50.0  0.511
   AST increased                        17.1                0           53.7   14.3   2.4   52.4  1.000
   ALT increased                        24.4                0           51.2   16.7    0    52.4  1.000
   Vomiting                               0                 0           48.8    0      0    23.8  0.023
   GGT increased                        29.3                0           46.3   31.0   4.8   50.0  0.827
   Pyrexia                                0                 0           43.9   4.8     0    57.1  0.190
   LDH increased                          0                 0           36.6    0      0    35.7  1.000
   Constipation                           0                 0           36.6    0      0    33.3  0.820
   ALP increased                         7.3                0           31.7   16.7    0    40.5  0.495
   Weight decreased                       0                 0           31.7    0      0    31.0  1.000
   Diarrhoea                             2.4                0           31.7    0      0    26.2  0.634
   Blood sodium decreased               17.1                0           31.7   9.5     0    19.0  0.214
   C-reactive protein increased           0                 0           26.8   7.1     0    52.4  0.025

Abbreviations: ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; GC=gemcitabine and cisplatin; GEM=gemcitabine; GGT=*γ*-glutamyltransferase; LDH=lactate dehydrogenase; RBC=red blood cell; WBC=white blood cell.

Events were graded according to CTCAE v3.0.
